Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer

被引:93
作者
Chappuis, PO
Kapusta, L
Bégin, LR
Wong, N
Brunet, JS
Narod, SA
Slingerland, J
Foulkes, WD
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Med, Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada
[3] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada
[4] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Surg, Montreal, PQ H3T 1E2, Canada
[5] McGill Univ, Ctr Hlth, Res Inst, Dept Med, Montreal, PQ H3T 1E2, Canada
[6] McGill Univ, Ctr Hlth, Res Inst, Dept Human Genet, Montreal, PQ H3T 1E2, Canada
[7] Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med, Toronto, ON, Canada
[8] Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Pathol, Toronto, ON, Canada
[9] Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Ctr Res Womens Hlth, Toronto, ON, Canada
关键词
D O I
10.1200/JCO.2000.18.24.4045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Decreased levels of the cyclin-dependent kinase inhibitor p27(Kip1) in breast cancer are associated with a poor outcome. The prognostic significance of BRCA1/2 mutations is less clear, and the relationship between BRCA1/2 mutation status, p27(Kip1) protein levels, and outcome has not been studied. Patients and Methods: pathology blocks from 202 consecutive Ashkenazi Jewish women with primary inversive breast cancer were studied. Tumor DNA was tested for the three common BRCA1/2 founder mutations present in Ashkenazi Jews, and p27(Kip1) expression was evaluated by immunohistochemistry. The median follow-up wets 6.4 years. Results: Thirty-two tumors (16%) were positive for a BRCA 1/2 mutation, Low p27(Kip1) expression was seen in 110 tumors (63%) and was significantly associated with BRCA 1/2 mutations (odds ratio, 4.0; 95% confidence in terval [CI], 1.4 to 11.1; P =.009), BRCA1/2 mutation carriers had a significantly worse 5-year distant disease-free survival (DDFS) compared with women without BRCA1/2 mutations (58% v 82%; P =.003). Similar results were seen for women whose tumors expressed low levels of p27(Kip1), compared with those with high levels (5-year DDFS, 68% v 93%; P <.0001), In a multivariate analysis, both BRCA1/2 mutation and low p27(Kip1) expression were associated with a shorter DDFS (relative risk [RR], 2.1; 95% CI, 1.0 to 4.3; P =.05; and RR, 3.9; 95% CI, 1.4 to 11.1; P =.01, respectively). Conclusion: In this study, we showed that BRCA1/2 mutations were associated with low levels of p27(Kip1) in breast cancer. Both BRCA1/2 and p27(Kip1) status were identified as independent prognostic factors, J Clin Oncol 18:4045-4052, (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:4045 / 4052
页数:8
相关论文
共 51 条
[1]   Survival in early-onset BRCA1 breast-cancer patients [J].
Ansquer, Y ;
Gautier, C ;
Fourquet, A ;
Asselain, B ;
Stoppa-Lyonnet, D .
LANCET, 1998, 352 (9127) :541-541
[2]   BRCA1 and BRCA2:: From molecular genetics to clinical medicine [J].
Blackwood, MA ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1969-1977
[3]   Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1 [J].
Cariou, S ;
Catzavelos, C ;
Slingerland, JM .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :29-41
[4]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[5]  
2-H
[6]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[7]   The influence of familial and hereditary factors on the prognosis of breast cancer [J].
Chappuis, PO ;
Rosenblatt, J ;
Foulkes, WD .
ANNALS OF ONCOLOGY, 1999, 10 (10) :1163-1170
[8]   p27 expression as a prognostic factor of breast cancer in Taiwan [J].
Chu, JS ;
Huang, CS ;
Chang, KJ .
CANCER LETTERS, 1999, 141 (1-2) :123-130
[9]   p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours [J].
Crook, T ;
Brooks, LA ;
Crossland, S ;
Osin, P ;
Barker, KT ;
Waller, J ;
Philp, E ;
Smith, PD ;
Yulug, I ;
Peto, J ;
Parker, G ;
Allday, MJ ;
Crompton, MR ;
Gusterson, BA .
ONCOGENE, 1998, 17 (13) :1681-1689
[10]   Tumor-related prognostic factors for breast cancer [J].
Donegan, WL .
CA-A CANCER JOURNAL FOR CLINICIANS, 1997, 47 (01) :28-51